AccenGen Therapeutics, Inc. is an early-stage pharmaceutical company focused on developing products using soluble epoxide hydrolase (sEH) inhibitors (sEHI) and dual sEH/COX inhibitors for indications with fibrotic etiologies and highest unmet needs. Our highest priority indication is treating pulmonary fibrosis, a disease worse than many cancers.
sEH studies have resulted in over 800 publications in top-tier peer-reviewed journals.
For something that touches us all.
sEH core technology platform allows multiple product opportunities and diversified risk.